Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors

BACKGROUND: Traditionally, vaccine development against the blood-stage of Plasmodium falciparum infection has focused on recombinant protein-adjuvant formulations in order to induce high-titer growth-inhibitory antibody responses. However, to date no such vaccine encoding a blood-stage antigen(s) al...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheehy, Susanne H., Duncan, Christopher J. A., Elias, Sean C., Biswas, Sumi, Collins, Katharine A., O'Hara, Geraldine A., Halstead, Fenella D., Ewer, Katie J., Mahungu, Tabitha, Spencer, Alexandra J., Miura, Kazutoyo, Poulton, Ian D., Dicks, Matthew D. J., Edwards, Nick J., Berrie, Eleanor, Moyle, Sarah, Colloca, Stefano, Cortese, Riccardo, Gantlett, Katherine, Long, Carole A., Lawrie, Alison M., Gilbert, Sarah C., Doherty, Tom, Nicosia, Alfredo, Hill, Adrian V. S., Draper, Simon J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3283618/
https://www.ncbi.nlm.nih.gov/pubmed/22363582
http://dx.doi.org/10.1371/journal.pone.0031208

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3283618/
https://www.ncbi.nlm.nih.gov/pubmed/22363582
http://dx.doi.org/10.1371/journal.pone.0031208

Ejemplares similares